Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
BIOFRONTERA INC (BFRI) Stock Price & Overview
NASDAQ:BFRI • US09077D2099
Current stock price
1.08 USD
0 (0%)
At close:
1.0922 USD
+0.01 (+1.13%)
After Hours:
The current stock price of BFRI is 1.08 USD. Today BFRI is down by 0%. In the past month the price increased by 10.22%. In the past year, price increased by 50%.
BFRI Key Statistics
52-Week Range0.536 - 1.19
Current BFRI stock price positioned within its 52-week range.
1-Month Range0.9454 - 1.17
Current BFRI stock price positioned within its 1-month range.
- Market Cap
- 12.582M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.18
- Dividend Yield
- N/A
BFRI Stock Performance
Today
0%
1 Week
N/A
1 Month
+10.22%
3 Months
+16.09%
Longer-term
6 Months -1.82%
1 Year +50.00%
2 Years +4.85%
3 Years -88.51%
5 Years N/A
10 Years N/A
BFRI Stock Chart
BFRI Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to BFRI. When comparing the yearly performance of all stocks, BFRI is one of the better performing stocks in the market, outperforming 84.79% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BFRI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BFRI. BFRI has a bad profitability rating. Also its financial health evaluation is rather negative.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BFRI Earnings
On March 19, 2026 BFRI reported an EPS of 0.48 and a revenue of 17.10M. The company beat EPS expectations (142.84% surprise) and beat revenue expectations (3.83% surprise).
Next Earnings DateMay 13, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported$0.48
Revenue Reported17.1M
EPS Surprise 142.84%
Revenue Surprise 3.83%
BFRI Forecast & Estimates
8 analysts have analysed BFRI and the average price target is 6.12 USD. This implies a price increase of 466.67% is expected in the next year compared to the current price of 1.08.
For the next year, analysts expect an EPS growth of 96.97% and a revenue growth 14.75% for BFRI
Analysts
Analysts82.5
Price Target6.12 (466.67%)
EPS Next Y96.97%
Revenue Next Year14.75%
BFRI Financial Highlights
Over the last trailing twelve months BFRI reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 71.71% compared to the year before.
Income Statements
Revenue(TTM)41.71M
Net Income(TTM)-10.54M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.89% | ||
| ROE | -100.53% | ||
| Debt/Equity | 0.44 |
Chartmill High Growth Momentum
EPS Q2Q%293.2%
Sales Q2Q%36.16%
EPS 1Y (TTM)71.71%
Revenue 1Y (TTM)11.75%
BFRI Ownership
Ownership
Inst Owners17.2%
Shares11.65M
Float9.25M
Ins Owners6.63%
Short Float %0.78%
Short Ratio0.5
BFRI Industry Overview
BFRI operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
41%
Outperformed 41% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.5
- Average Fwd P/E
- 17.7
- Average Debt/Equity
- 1.2
BFRI Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.43 | 269.662B | ||
| PFE | PFIZER INC | 8.81 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 123.709B | ||
| ZTS | ZOETIS INC | 16.14 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.899B | ||
| VTRS | VIATRIS INC | 6.03 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BFRI
Company Profile
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The firm commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
Company Info
IPO: 2021-10-14
BIOFRONTERA INC
120 Presidential Way,, Suite 330
Woburn MASSACHUSETTS US
CEO: Erica Monaco
Employees: 89
Phone: 18004831140
BIOFRONTERA INC / BFRI FAQ
What does BFRI do?
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 92 full-time employees. The company went IPO on 2021-10-14. The firm specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The firm commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
What is the current price of BFRI stock?
The current stock price of BFRI is 1.08 USD.
Does BIOFRONTERA INC pay dividends?
BFRI does not pay a dividend.
What is the ChartMill rating of BIOFRONTERA INC stock?
BFRI has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of BFRI stock?
BIOFRONTERA INC (BFRI) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for BIOFRONTERA INC?
BIOFRONTERA INC (BFRI) has a market capitalization of 12.58M USD. This makes BFRI a Nano Cap stock.
Can you provide the upcoming earnings date for BIOFRONTERA INC?
BIOFRONTERA INC (BFRI) will report earnings on 2026-05-13.